官方服务：
资源简介：
RNA-seq of MC903-induced recurrence atopic dermatitis (AD) mice with Ku-Gan topical treatment
应用场景：
创建时间：
2024-01-30
相关数据集
Additional file 1 of A novel sphingosylphosphorylcholine and sphingosine-1-phosphate receptor 1 antagonist, KRO-105714, for alleviating atopic dermatitis
Additional file 1: Supplementary data. A novel sphingosylphosphorylcholine and sphingosine-1-phosphate receptor 1 antagonist, KRO-105714, for alleviating atopic dermatitis. Supplementary figure 1. NMR
DataCite Commons2020-08-25 更新130
Amygdalin alleviates atopic dermatitis-like skin inflammation via inhibition of Th2 immune responses
Atopic dermatitis (AD) is a chronic skin disease marked by immune dysregulation such as upregulated T helper (Th) 2 responses. While Th2-targeted therapies for AD are under development, their applicat
DataCite Commons2025-09-29 更新110
Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
Though Janus kinase inhibitors such as upadacitinib rapidly relieve itch in atopic dermatitis (AD) patients, how early itch relief impacts later skin clearance is not examined. This study aims to dete
DataCite Commons2024-12-16 更新90
Additional file 9: Table E5. of Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways
Khattri 2014 (GSE58558) – Ingenuity Pathway Analysis. (XLSX 26 kb)
DataCite Commons2024-12-18 更新120
A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis. A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis
A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD). Overall design: Patients were ra
NIAID Data Ecosystem100
